Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt 13.65
IPSEY's Cash to Debt is ranked higher than
82% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. IPSEY: 13.65 )
IPSEY' s 10-Year Cash to Debt Range
Min: 1.56   Max: No Debt
Current: 13.65

Equity to Asset 0.62
IPSEY's Equity to Asset is ranked higher than
70% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. IPSEY: 0.62 )
IPSEY' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.66
Current: 0.62

0.28
0.66
Interest Coverage No Debt
IPSEY's Interest Coverage is ranked higher than
85% of the 490 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 89.59 vs. IPSEY: No Debt )
IPSEY' s 10-Year Interest Coverage Range
Min: 39.21   Max: 9999.99
Current: No Debt

39.21
9999.99
F-Score: 9
Z-Score: 4.90
M-Score: -2.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.88
IPSEY's Operating margin (%) is ranked higher than
84% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.55 vs. IPSEY: 14.88 )
IPSEY' s 10-Year Operating margin (%) Range
Min: 6   Max: 21.02
Current: 14.88

6
21.02
Net-margin (%) 11.90
IPSEY's Net-margin (%) is ranked higher than
84% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.93 vs. IPSEY: 11.90 )
IPSEY' s 10-Year Net-margin (%) Range
Min: -2.19   Max: 15.29
Current: 11.9

-2.19
15.29
ROE (%) 16.24
IPSEY's ROE (%) is ranked higher than
92% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.26 vs. IPSEY: 16.24 )
IPSEY' s 10-Year ROE (%) Range
Min: -2.91   Max: 30
Current: 16.24

-2.91
30
ROA (%) 9.74
IPSEY's ROA (%) is ranked higher than
91% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.06 vs. IPSEY: 9.74 )
IPSEY' s 10-Year ROA (%) Range
Min: -1.75   Max: 15.26
Current: 9.74

-1.75
15.26
ROC (Joel Greenblatt) (%) 48.67
IPSEY's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.08 vs. IPSEY: 48.67 )
IPSEY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 17.96   Max: 105.8
Current: 48.67

17.96
105.8
Revenue Growth (%) 5.80
IPSEY's Revenue Growth (%) is ranked higher than
70% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. IPSEY: 5.80 )
IPSEY' s 10-Year Revenue Growth (%) Range
Min: -61.3   Max: 5.8
Current: 5.8

-61.3
5.8
EBITDA Growth (%) 9.70
IPSEY's EBITDA Growth (%) is ranked higher than
77% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.20 vs. IPSEY: 9.70 )
IPSEY' s 10-Year EBITDA Growth (%) Range
Min: -55.7   Max: 9.7
Current: 9.7

-55.7
9.7
EPS Growth (%) 14.60
IPSEY's EPS Growth (%) is ranked higher than
80% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. IPSEY: 14.60 )
IPSEY' s 10-Year EPS Growth (%) Range
Min: -20.5   Max: 14.6
Current: 14.6

-20.5
14.6
» IPSEY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

IPSEY Guru Trades in

IPSEY Guru Trades in

IPSEY Guru Trades in

Q3 2012

IPSEY Guru Trades in Q3 2012

Vanguard Health Care Fund 1,400,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with IPSEY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.50
IPSEY's P/E(ttm) is ranked higher than
88% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.90 vs. IPSEY: 21.50 )
IPSEY' s 10-Year P/E(ttm) Range
Min: 3.01   Max: 2432.5
Current: 21.5

3.01
2432.5
P/B 3.40
IPSEY's P/B is ranked higher than
70% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.39 vs. IPSEY: 3.40 )
IPSEY' s 10-Year P/B Range
Min: 1.52   Max: 4.81
Current: 3.4

1.52
4.81
P/S 2.50
IPSEY's P/S is ranked higher than
78% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.81 vs. IPSEY: 2.50 )
IPSEY' s 10-Year P/S Range
Min: 0.46   Max: 3.65
Current: 2.5

0.46
3.65
PFCF 26.00
IPSEY's PFCF is ranked higher than
91% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. IPSEY: 26.00 )
IPSEY' s 10-Year PFCF Range
Min: 2.4   Max: 46.82
Current: 26

2.4
46.82
EV-to-EBIT 13.92
IPSEY's EV-to-EBIT is ranked higher than
91% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.14 vs. IPSEY: 13.92 )
IPSEY' s 10-Year EV-to-EBIT Range
Min: 1   Max: 26.3
Current: 13.92

1
26.3
PEG 15.27
IPSEY's PEG is ranked higher than
81% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. IPSEY: 15.27 )
IPSEY' s 10-Year PEG Range
Min: 10.99   Max: 15.3
Current: 15.27

10.99
15.3
Shiller P/E 35.40
IPSEY's Shiller P/E is ranked higher than
84% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.02 vs. IPSEY: 35.40 )
IPSEY' s 10-Year Shiller P/E Range
Min: 6.94   Max: 35.86
Current: 35.4

6.94
35.86
Current Ratio 1.60
IPSEY's Current Ratio is ranked higher than
61% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. IPSEY: 1.60 )
IPSEY' s 10-Year Current Ratio Range
Min: 1.39   Max: 2.33
Current: 1.6

1.39
2.33
Quick Ratio 1.28
IPSEY's Quick Ratio is ranked higher than
63% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. IPSEY: 1.28 )
IPSEY' s 10-Year Quick Ratio Range
Min: 1.1   Max: 2.03
Current: 1.28

1.1
2.03

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.40
IPSEY's Dividend Yield is ranked higher than
76% of the 485 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.35 vs. IPSEY: 1.40 )
IPSEY' s 10-Year Dividend Yield Range
Min: 1.39   Max: 4.36
Current: 1.4

1.39
4.36
Dividend Payout 0.30
IPSEY's Dividend Payout is ranked higher than
82% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. IPSEY: 0.30 )
IPSEY' s 10-Year Dividend Payout Range
Min: 0.34   Max: 80
Current: 0.3

0.34
80
Dividend growth (3y) 2.20
IPSEY's Dividend growth (3y) is ranked higher than
78% of the 356 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.50 vs. IPSEY: 2.20 )
IPSEY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 7.7
Current: 2.2

0
7.7
Yield on cost (5-Year) 1.65
IPSEY's Yield on cost (5-Year) is ranked higher than
78% of the 493 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.37 vs. IPSEY: 1.65 )
IPSEY' s 10-Year Yield on cost (5-Year) Range
Min: 1.64   Max: 5.15
Current: 1.65

1.64
5.15
Share Buyback Rate 0.50
IPSEY's Share Buyback Rate is ranked higher than
86% of the 584 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -1.30 vs. IPSEY: 0.50 )
IPSEY' s 10-Year Share Buyback Rate Range
Min: 0.5   Max: -187.2
Current: 0.5

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.90
IPSEY's Price/Tangible Book is ranked higher than
65% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.72 vs. IPSEY: 5.90 )
IPSEY' s 10-Year Price/Tangible Book Range
Min: 3.09   Max: 7.14
Current: 5.9

3.09
7.14
Price/DCF (Projected) 1.60
IPSEY's Price/DCF (Projected) is ranked higher than
88% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.02 vs. IPSEY: 1.60 )
IPSEY' s 10-Year Price/DCF (Projected) Range
Min: 0.81   Max: 1.5
Current: 1.6

0.81
1.5
Price/Median PS Value 1.20
IPSEY's Price/Median PS Value is ranked higher than
70% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.27 vs. IPSEY: 1.20 )
IPSEY' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 1.72
Current: 1.2

0.23
1.72
Price/Graham Number 2.40
IPSEY's Price/Graham Number is ranked higher than
80% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.67 vs. IPSEY: 2.40 )
IPSEY' s 10-Year Price/Graham Number Range
Min: 1.65   Max: 2.59
Current: 2.4

1.65
2.59
Earnings Yield (Greenblatt) 7.10
IPSEY's Earnings Yield (Greenblatt) is ranked higher than
86% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.90 vs. IPSEY: 7.10 )
IPSEY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.8   Max: 103
Current: 7.1

3.8
103
Forward Rate of Return (Yacktman) 4.69
IPSEY's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 668 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. IPSEY: 4.69 )
IPSEY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -25.8   Max: 6.7
Current: 4.69

-25.8
6.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:0MH6.country, IPNNV.France, IPN.France, I7G.Germany
Ipsen is a France based biotechnology specialty care company that produces drugs for uro-oncology, endocrinology, neurology and hematology, and primary care.
» More Articles for OTCPK:IPSEY

Headlines

Articles On GuruFocus.com

More From Other Websites
Ipsen Biopharmaceuticals, Inc. Announces Key Medical and Commercial Hires Sep 10 2014
Ipsen Announces Acceptance of Filings for Somatuline® in the Treatment of GEP-NETs1 in the US with... Sep 01 2014
Ipsen Announces Acceptance of Filings for Somatuline® in the Treatment of GEP-NET1s in the US with... Sep 01 2014
Ipsen: 2014 Half-Year Results and 2014 Objectives Aug 29 2014
Ipsen Announces Second Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in... Aug 26 2014
Ipsen Appoints Cynthia Schwalm as President and CEO of Ipsen North America Aug 20 2014
New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in... Jul 17 2014
New England Journal of Medicine Publishes Ipsen’s Somatuline® CLARINET® Phase III Results in... Jul 16 2014
Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US,... Jul 11 2014
Ordinary Shareholders’ Meeting of IPSEN S.A. held on 4 June 2014 Jun 04 2014
BofA/Merrill pharmaceuticals analysts hold an analyst/industry conference call May 22 2014
Ipsen announces supply of Increlex will be available in U.S. May 13 2014
Ipsen Announces a Step Forward in the Resupply of Increlex® (Mecasermin [rDNA Origin] Injection) in... May 13 2014
Ipsen Announces a Step Forward in the Resupply of Increlex® in the U.S. May 13 2014
Ipsen Announces Name Change for its Research and Development Affiliate in the U.S. From Biomeasure... May 06 2014
Ipsen’s first quarter 2014 sales Apr 30 2014
Ipsen eligible for PEA-PME and included in CAC® PME index by Euronext Apr 09 2014
Ipsen In Good Shape Jan 24 2014
Ipsen, GW enter into agreement to distribute Sativex in Latin America Jan 14 2014
New 62,600 Square Foot Lease At 650 East Kendall Street Signed By Ipsen And BioMed Realty Sep 26 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK